Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | FLT4 | P35916 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL7866 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL465143 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351046 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28098790 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29371159 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL2770155 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28097850 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL11776 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL30887946 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2659 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| EP-4376874-B1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20260014140-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2026-01-15 | — | — | US | claimed |
| US-20260001948-A1 | Targeting the Interplay of Treg Cells and Hepatic Stellate Cells in Liver Fibrosis and Insulin Resistance | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025264604-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-3980561-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG, COLORECTAL AND BREAST CANCER | Sitokine Limited (GB) | 2022-04-13 | — | — | EP | claimed |
| WO-2022066825-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-03-31 | — | — | WO | claimed |
| CN-114206435-A | Treatment of central nervous system disorders | 诺欧生物有限责任公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3963332-A1 | BIOMARKERS FOR DISEASE PROGRESSION IN SQUAMOUS CELL CARCINOMA | AMLO Biosciences Limited (GB) | 2022-03-09 | — | — | EP | claimed |
| US-20220062195-A1 | CURCUPHENOL COMPOUNDS FOR INCREASING MHC-I EXPRESSION | Cava Healthcare Inc. (CA) | 2022-03-03 | — | — | US | claimed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220054648-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | IMMUNOMEDICS, INC. | 2022-02-24 | — | — | US | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022026829-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR SKIN TOXICITY | ANAPTYSBIO, INC. (US) | 2022-02-03 | — | — | WO | claimed |